文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.

作者信息

Stefanova Denitsa, Yordanov Yordan, Bogdanova Radostina, Voycheva Christina, Tzankov Borislav, Popova Teodora, Kondeva-Burdina Magdalena, Tzankova Virginia, Toncheva-Moncheva Natalia, Tzankova Diana, Slavkova Marta

机构信息

Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.

出版信息

Pharmaceutics. 2025 Mar 4;17(3):331. doi: 10.3390/pharmaceutics17030331.


DOI:10.3390/pharmaceutics17030331
PMID:40142995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11945150/
Abstract

: Natural substances have been a widely studied source of both pharmaceutical excipients and drugs. Berberine (BRB) is a benzylisoquinoline alkaloid isolated from different plant sources. It possesses various pharmacological properties including antibacterial, antitumor, antidiabetic, neuroprotective, hepatoprotective, anti-inflammatory, antioxidant, etc. However, the limited aqueous solubility hinders its application. Nanosized drug delivery systems are an innovative approach for addressing various challenges regarding drug delivery via different routes of administration. Their utilization could improve the solubility of active constituents. : A melt-emulsification and ultrasonication technique was applied for the preparation of nanostructured lipid carriers (NLCs). They were thoroughly physicochemically characterized by the means of Dynamic Light Scattering, TEM, FTIR, DSC, TGA, and In Vitro release. The In Vitro efficacy and safety were evaluated on cholangiocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, lymphoma, fibroblast, and cardioblast cells, as well as rat liver microsomes by means of cytotoxicity assays and the comet assay. : The obtained nanoparticles had a spherical shape and size around 158.2 ± 1.8 nm with negative zeta potential. They revealed successful drug loading and improved dissolution of berberine in physiological conditions. The In Vitro safety studies showed that loading BRB in NLCs resulted in improved or retained cytotoxicity to tumor cell lines and reduced cytotoxicity to normal cell lines and liver microsomes. The NLC itself increased microsomal malondialdehyde (MDA) and comet formation. : A successful preparation of NLCs with berberine is presented. The nanocarriers show favorable physicochemical and biopharmaceutical properties. The cellular experiments show that the NLC loading of berberine could improve its anticancer efficacy and safety. These findings highlight the potential applicability of berberine in gastrointestinal neoplasms and build the foundation for future practical translation.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/430ad477fb25/pharmaceutics-17-00331-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/19511741865d/pharmaceutics-17-00331-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/63351863ba71/pharmaceutics-17-00331-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/16bc67947c6a/pharmaceutics-17-00331-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/3491ec7f9c07/pharmaceutics-17-00331-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/cd10f1906d1b/pharmaceutics-17-00331-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/42dcdd5957ba/pharmaceutics-17-00331-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/55e018221e22/pharmaceutics-17-00331-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/1dbe6baee563/pharmaceutics-17-00331-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/4f6d3646e233/pharmaceutics-17-00331-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/dc268017a583/pharmaceutics-17-00331-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/2ee121ffa914/pharmaceutics-17-00331-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/b13ae8190e50/pharmaceutics-17-00331-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/430ad477fb25/pharmaceutics-17-00331-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/19511741865d/pharmaceutics-17-00331-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/63351863ba71/pharmaceutics-17-00331-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/16bc67947c6a/pharmaceutics-17-00331-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/3491ec7f9c07/pharmaceutics-17-00331-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/cd10f1906d1b/pharmaceutics-17-00331-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/42dcdd5957ba/pharmaceutics-17-00331-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/55e018221e22/pharmaceutics-17-00331-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/1dbe6baee563/pharmaceutics-17-00331-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/4f6d3646e233/pharmaceutics-17-00331-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/dc268017a583/pharmaceutics-17-00331-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/2ee121ffa914/pharmaceutics-17-00331-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/b13ae8190e50/pharmaceutics-17-00331-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/11945150/430ad477fb25/pharmaceutics-17-00331-g013.jpg

相似文献

[1]
In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.

Pharmaceutics. 2025-3-4

[2]
Berberine loaded nanostructured lipid carrier for Alzheimer's disease: Design, statistical optimization and enhanced in vivo performance.

Life Sci. 2021-11-15

[3]
Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis.

Int J Nanomedicine. 2020-6-3

[4]
Nanoparticles based on complex of berberine chloride and polymethacrylic or polyacrylic acid with antioxidant and in vitro antitumor activities.

Int J Pharm. 2020-6-30

[5]
Nanostructured lipid carriers as a strategy for encapsulation of active plant constituents: Formulation and in vitro physicochemical characterizations.

Chem Phys Lipids. 2021-3

[6]
Luliconazole-loaded nanostructured lipid carrier: formulation, characterization, and in vitro antifungal evaluation against a panel of resistant fungal strains.

Sci Rep. 2024-12-28

[7]
Preparation, characterization, and evaluation of perphenazine-loaded nanostructured lipid carriers for oral bioavailability improvement.

Drug Dev Ind Pharm. 2021-3

[8]
Optimized Nanostructured Lipid Carriers for Metformin: Enhanced Anti-Inflammatory Activity and Protection Against Type 2 Diabetes-Induced Organ Damage.

Int J Nanomedicine. 2025-3-24

[9]
Nanostructured Lipid Carrier-Based Gel for Repurposing Simvastatin in Localized Treatment of Breast Cancer: Formulation Design, Development, and In Vitro and In Vivo Characterization.

AAPS PharmSciTech. 2023-4-21

[10]
Pectin coated nanostructured lipid carriers for targeted piperine delivery to hepatocellular carcinoma.

Int J Pharm. 2022-5-10

本文引用的文献

[1]
Revisiting nanomedicine design strategies for follow-on products: A model-informed approach to optimize performance.

J Control Release. 2024-12

[2]
Transforming Cancer Treatment with Nanotechnology: The Role of Berberine as a Star Natural Compound.

Int J Nanomedicine. 2024

[3]
A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.

ACS Nano. 2024-2-27

[4]
Cancer treatment therapies: traditional to modern approaches to combat cancers.

Mol Biol Rep. 2023-11

[5]
The therapeutic effects of berberine for gastrointestinal cancers.

Asia Pac J Clin Oncol. 2024-4

[6]
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.

J Control Release. 2023-2

[7]
Preparation, physicochemical characterization, and bioactivity evaluation of berberine-entrapped albumin nanoparticles.

Sci Rep. 2022-10-19

[8]
Nutraceuticals and Food-Grade Lipid Nanoparticles: From Natural Sources to a Circular Bioeconomy Approach.

Foods. 2022-8-3

[9]
Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.

Molecules. 2022-6-9

[10]
Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology.

ACS Nano. 2022-7-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索